Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication

Bor Shyang Sheu, Yu Ching Tsai, Chung Tai Wu, Wei Lun Chang, Hsiu Chi Cheng, Hsiao Bai Yang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background and Aim: Intestinal metaplasia (IM) has overexpressions of COX-2. Short-term 8-week celecoxib, a selective COX-2 inhibitor, exerts a preliminary hint to improve regression in part for persistent IM after Helicobacter pylori eradication. This study further validated whether or not a prolonged duration of celecoxib of up to 1 year can be safe and effective. Methods: One hundred and forty patients, with persistent IM after H. pylori eradication for 1 year, were included with half of them receiving celecoxib 200 mg/day for 12 months and the other half serving as controls. Each patient received serial checkups of blood creatinine levels every 4 months. After the 1-year follow-up, panendoscopy was repeated to assess the IM regression. The serial gastric specimens, taken before and after celecoxib therapy, were immunochemically stained for COX-2. Results: The intention-to-treat (ITT) and per-protocol (PP) analyses to the rates of IM regression were higher in the celecoxib group than in the controls (ITT: 44.3% [31/70] vs 14.3% [10/70], p < .001; and PP: 51.7% [31/60] vs 16.1% [10/62], p < .001). All enrolled patients had no renal impairment during follow-up. Even in the patients without IM regression, the mean IM scores and COX-2 expressions were significantly more decreased in the celecoxib group than in the controls (p < .005). Conclusion: One year 200-mg celecoxib daily be safely administered to improve the regression or prevent the progression of persistent IM after H. pylori eradication.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalHelicobacter
Volume18
Issue number2
DOIs
Publication statusPublished - 2013 Apr 1

Fingerprint

Celecoxib
Pylorus
Metaplasia
Stomach
Control Groups
Cyclooxygenase 2 Inhibitors
Helicobacter pylori

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Infectious Diseases

Cite this

@article{f303429e239c4adb84300f16697dabdb,
title = "Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication",
abstract = "Background and Aim: Intestinal metaplasia (IM) has overexpressions of COX-2. Short-term 8-week celecoxib, a selective COX-2 inhibitor, exerts a preliminary hint to improve regression in part for persistent IM after Helicobacter pylori eradication. This study further validated whether or not a prolonged duration of celecoxib of up to 1 year can be safe and effective. Methods: One hundred and forty patients, with persistent IM after H. pylori eradication for 1 year, were included with half of them receiving celecoxib 200 mg/day for 12 months and the other half serving as controls. Each patient received serial checkups of blood creatinine levels every 4 months. After the 1-year follow-up, panendoscopy was repeated to assess the IM regression. The serial gastric specimens, taken before and after celecoxib therapy, were immunochemically stained for COX-2. Results: The intention-to-treat (ITT) and per-protocol (PP) analyses to the rates of IM regression were higher in the celecoxib group than in the controls (ITT: 44.3{\%} [31/70] vs 14.3{\%} [10/70], p < .001; and PP: 51.7{\%} [31/60] vs 16.1{\%} [10/62], p < .001). All enrolled patients had no renal impairment during follow-up. Even in the patients without IM regression, the mean IM scores and COX-2 expressions were significantly more decreased in the celecoxib group than in the controls (p < .005). Conclusion: One year 200-mg celecoxib daily be safely administered to improve the regression or prevent the progression of persistent IM after H. pylori eradication.",
author = "Sheu, {Bor Shyang} and Tsai, {Yu Ching} and Wu, {Chung Tai} and Chang, {Wei Lun} and Cheng, {Hsiu Chi} and Yang, {Hsiao Bai}",
year = "2013",
month = "4",
day = "1",
doi = "10.1111/hel.12013",
language = "English",
volume = "18",
pages = "117--123",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "2",

}

Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication. / Sheu, Bor Shyang; Tsai, Yu Ching; Wu, Chung Tai; Chang, Wei Lun; Cheng, Hsiu Chi; Yang, Hsiao Bai.

In: Helicobacter, Vol. 18, No. 2, 01.04.2013, p. 117-123.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication

AU - Sheu, Bor Shyang

AU - Tsai, Yu Ching

AU - Wu, Chung Tai

AU - Chang, Wei Lun

AU - Cheng, Hsiu Chi

AU - Yang, Hsiao Bai

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Background and Aim: Intestinal metaplasia (IM) has overexpressions of COX-2. Short-term 8-week celecoxib, a selective COX-2 inhibitor, exerts a preliminary hint to improve regression in part for persistent IM after Helicobacter pylori eradication. This study further validated whether or not a prolonged duration of celecoxib of up to 1 year can be safe and effective. Methods: One hundred and forty patients, with persistent IM after H. pylori eradication for 1 year, were included with half of them receiving celecoxib 200 mg/day for 12 months and the other half serving as controls. Each patient received serial checkups of blood creatinine levels every 4 months. After the 1-year follow-up, panendoscopy was repeated to assess the IM regression. The serial gastric specimens, taken before and after celecoxib therapy, were immunochemically stained for COX-2. Results: The intention-to-treat (ITT) and per-protocol (PP) analyses to the rates of IM regression were higher in the celecoxib group than in the controls (ITT: 44.3% [31/70] vs 14.3% [10/70], p < .001; and PP: 51.7% [31/60] vs 16.1% [10/62], p < .001). All enrolled patients had no renal impairment during follow-up. Even in the patients without IM regression, the mean IM scores and COX-2 expressions were significantly more decreased in the celecoxib group than in the controls (p < .005). Conclusion: One year 200-mg celecoxib daily be safely administered to improve the regression or prevent the progression of persistent IM after H. pylori eradication.

AB - Background and Aim: Intestinal metaplasia (IM) has overexpressions of COX-2. Short-term 8-week celecoxib, a selective COX-2 inhibitor, exerts a preliminary hint to improve regression in part for persistent IM after Helicobacter pylori eradication. This study further validated whether or not a prolonged duration of celecoxib of up to 1 year can be safe and effective. Methods: One hundred and forty patients, with persistent IM after H. pylori eradication for 1 year, were included with half of them receiving celecoxib 200 mg/day for 12 months and the other half serving as controls. Each patient received serial checkups of blood creatinine levels every 4 months. After the 1-year follow-up, panendoscopy was repeated to assess the IM regression. The serial gastric specimens, taken before and after celecoxib therapy, were immunochemically stained for COX-2. Results: The intention-to-treat (ITT) and per-protocol (PP) analyses to the rates of IM regression were higher in the celecoxib group than in the controls (ITT: 44.3% [31/70] vs 14.3% [10/70], p < .001; and PP: 51.7% [31/60] vs 16.1% [10/62], p < .001). All enrolled patients had no renal impairment during follow-up. Even in the patients without IM regression, the mean IM scores and COX-2 expressions were significantly more decreased in the celecoxib group than in the controls (p < .005). Conclusion: One year 200-mg celecoxib daily be safely administered to improve the regression or prevent the progression of persistent IM after H. pylori eradication.

UR - http://www.scopus.com/inward/record.url?scp=84875023974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875023974&partnerID=8YFLogxK

U2 - 10.1111/hel.12013

DO - 10.1111/hel.12013

M3 - Article

C2 - 23067366

AN - SCOPUS:84875023974

VL - 18

SP - 117

EP - 123

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 2

ER -